Clinical trialPhase 3Active not recruiting
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Phase 3
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 13 December 2024
- Expected end
- 30 November 2030
- Enrollment
- 610 participants
- Sites
- 111
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Industry
- Results posted
- No
- Last update
- 2 November 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.